Pancreatitis Associated with Valproic Acid Therapy

Paul B. Batalden; Bruce J. Van Dyne; James Cloyd

doi:10.1542/peds.64.4.520

Pancreatitis Associated with Valproic Acid Therapy

PEDIATRICS ◽

10.1542/peds.64.4.520 ◽

1979 ◽

Vol 64 (4) ◽

pp. 520-522

Author(s):

Paul B. Batalden ◽

Bruce J. Van Dyne ◽

James Cloyd

Keyword(s):

Valproic Acid ◽

Acute Pancreatitis ◽

The Other ◽

Acid Therapy ◽

Valproic Acid Therapy

The development of acute pancreatitis in an 8-year-old boy being treated with valproic acid for simple absence spells is documented. A brief discussion of the other previously reported complications with valproic acid is included.

Acute pancreatitis and hyperammonemia in a hemodialysis patient during valproic acid therapy: A case report.

Nihon Toseki Igakkai Zasshi ◽

10.4009/jsdt.27.53 ◽

1994 ◽

Vol 27 (1) ◽

pp. 53-57 ◽

Cited By ~ 1

Author(s):

Toshiyuki Kamijo ◽

Toshikazu Sato ◽

Ryozo Yanagizawa ◽

Hiroichi Kishi

Keyword(s):

Valproic Acid ◽

Acute Pancreatitis ◽

Case Report ◽

Hemodialysis Patient ◽

Acid Therapy ◽

Valproic Acid Therapy

Acute Pancreatitis as a Complication of Antiepileptic Treatment: Case Series and Review of the Literature

Pediatric Reports ◽

10.3390/pediatric13010014 ◽

2021 ◽

Vol 13 (1) ◽

pp. 98-103

Author(s):

Agnieszka Pawłowska-Kamieniak ◽

Paulina Krawiec ◽

Elżbieta Pac-Kożuchowska

Keyword(s):

Valproic Acid ◽

Acute Pancreatitis ◽

Metabolic Disorders ◽

Genetic Factors ◽

Clinical Symptoms ◽

Gallstone Disease ◽

Young Patients ◽

Case Series ◽

Review Of The Literature ◽

Acid Therapy

Acute pancreatitis (AP) appears to be rare disease in childhood. In children, it has a different aetiology and course, and requires different management than in adult patients. The diagnosis of AP is based on at least two of the three criteria, which include typical clinical symptoms, abnormalities in laboratory tests and/or imaging studies of the pancreas. There are many known causes leading to AP in children including infections, blunt abdominal trauma, genetic factors, gallstone disease, metabolic disorders, anatomical defects of the pancreas, systemic diseases, as well as drugs, including antiepileptic drugs, and especially preparations of valproic acid. In our study, we present four cases of young patients diagnosed with acute pancreatitis as a complication of valproic acid therapy and we present a review of the literature. We believe that the activity of pancreatic enzymes should be monitored in children treated with valproate preparations in the case of clinical symptoms suggesting AP.

Association of genetic variants in six candidate genes with valproic acid therapy optimization

Pharmacogenomics ◽

10.2217/pgs.11.64 ◽

2011 ◽

Vol 12 (8) ◽

pp. 1107-1117 ◽

Cited By ~ 36

Author(s):

Chin-Chuan Hung ◽

Jia-Ling Ho ◽

Wei-Lun Chang ◽

John Jen Tai ◽

Tsung-Jen Hsieh ◽

...

Keyword(s):

Valproic Acid ◽

Candidate Genes ◽

Genetic Variants ◽

Acid Therapy ◽

Valproic Acid Therapy

Thrombocytopenia can occur after several months of valproic acid therapy

Inpharma Weekly ◽

10.2165/00128413-200314100-00042 ◽

2003 ◽

Vol &NA; (1410) ◽

pp. 17

Author(s):

&NA;

Keyword(s):

Valproic Acid ◽

Acid Therapy ◽

Valproic Acid Therapy

Effect of Valproic Acid Therapy on Zinc Metabolism in Children with Primary Epilepsy

Clinical Neuropharmacology ◽

10.1097/00002826-198702000-00008 ◽

1987 ◽

Vol 10 (1) ◽

pp. 80-86 ◽

Cited By ~ 12

Author(s):

T. Lerman-Sagie ◽

M. Statter ◽

G. Szabo ◽

P. Lerman

Keyword(s):

Valproic Acid ◽

Zinc Metabolism ◽

Acid Therapy ◽

Valproic Acid Therapy

The Role of Carnitine Supplementation during Valproic Acid Therapy

Annals of Pharmacotherapy ◽

10.1345/aph.19242 ◽

2000 ◽

Vol 34 (5) ◽

pp. 630-638 ◽

Cited By ~ 82

Author(s):

Jackie Y Raskind ◽

Gladys M El-Chaar

Keyword(s):

Valproic Acid ◽

Advisory Committee ◽

Randomized Clinical Trials ◽

Pediatric Population ◽

Carnitine Deficiency ◽

Carnitine Supplementation ◽

Acid Therapy ◽

Pediatric Neurology ◽

Valproic Acid Therapy

OBJECTIVE: To review the pathophysiology and significance of valproic acid–induced carnitine deficiency; to present and evaluate the literature pertaining to carnitine supplementation in pediatric patients receiving valproic acid; and to present the consensus guidelines for carnitine supplementation during valproic acid therapy. DATA SOURCES: A MEDLINE search (1966–December 1998) restricted to English-language literature, using MeSH headings of carnitine and valproic acid, was conducted to identify clinically relevant articles. Selected articles and references focusing on the pediatric population were included for review. DATA EXTRACTION: Study design, patient population, methods, and clinical outcomes were evaluated. DATA SYNTHESIS: Valproic acid, a widely used antiepileptic agent in the pediatric population, is limited by a 1/800 incidence of fatal hepatotoxicity in children under the age of two years. Carnitine is an essential amino acid necessary in β-oxidation of fatty acids and energy production in cellular mitochondria. It has been hypothesized that valproic acid may induce a carnitine deficiency in children and cause nonspecific symptoms of deficiency, hepatotoxicity, and hyperammonemia. Relevant published case reports and trials studying this relationship are evaluated, and a consensus statement by the Pediatric Neurology Advisory Committee is reviewed. CONCLUSIONS: Despite the lack of prospective, randomized clinical trials documenting efficacy of carnitine supplementation in preventing valproic acid–induced hepatotoxicity, the few limited studies available have shown carnitine supplementation to result in subjective and objective improvements along with increases in carnitine serum concentrations in patients receiving valproic acid. The Pediatric Neurology Advisory Committee in 1996 provided more concrete indications on the role of carnitine in valproic acid therapy, such as valproic acid overdose and valproic acid–induced hepatotoxicity. Carnitine was strongly recommended for children at risk of developing a carnitine deficiency. Although carnitine has been well tolerated, future studies are needed to evaluate the efficacy of prophylactic carnitine supplementation for the prevention of hepatotoxicity.